Cargando…
N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine
Porcine epidemic diarrhea virus (PEDV) is a contagious coronavirus infecting pigs that leads to significant economic losses in the swine industry. Given that PEDV infection occurs in gut epithelial cells mainly via the fecal-oral route, induction of PEDV-specific immune responses in the mucosal comp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Immunologists
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026690/ https://www.ncbi.nlm.nih.gov/pubmed/29984039 http://dx.doi.org/10.4110/in.2018.18.e21 |
_version_ | 1783336485884264448 |
---|---|
author | Kim, Sae-Hae Cho, Byeol-Hee Lee, Kyung-Yeol Jang, Yong-Suk |
author_facet | Kim, Sae-Hae Cho, Byeol-Hee Lee, Kyung-Yeol Jang, Yong-Suk |
author_sort | Kim, Sae-Hae |
collection | PubMed |
description | Porcine epidemic diarrhea virus (PEDV) is a contagious coronavirus infecting pigs that leads to significant economic losses in the swine industry. Given that PEDV infection occurs in gut epithelial cells mainly via the fecal-oral route, induction of PEDV-specific immune responses in the mucosal compartment is required for protective immunity against viral infection. However, an effective mucosal vaccine against the currently prevalent PEDV strain is not available. In this study, we demonstrated that the N-terminal domain (NTD) of the spike (S) protein of PEDV represents a new vaccine candidate molecule to be applied via the mucosal route. We first established an Escherichia coli expression system producing the partial NTD (NTD(231–501)) of the PEDV S protein. Orally administered NTD(231–501) protein specifically interacted with the apical area of M cells in the follicle-associated epithelium of Peyer's patch. Additionally, the NTD protein induced antigen-specific immune responses in both the systemic and mucosal immune compartments when administered orally. Collectively, we propose the NTD of the PEDV S protein to be a candidate mucosal vaccine molecule. |
format | Online Article Text |
id | pubmed-6026690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Korean Association of Immunologists |
record_format | MEDLINE/PubMed |
spelling | pubmed-60266902018-07-06 N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine Kim, Sae-Hae Cho, Byeol-Hee Lee, Kyung-Yeol Jang, Yong-Suk Immune Netw Original Article Porcine epidemic diarrhea virus (PEDV) is a contagious coronavirus infecting pigs that leads to significant economic losses in the swine industry. Given that PEDV infection occurs in gut epithelial cells mainly via the fecal-oral route, induction of PEDV-specific immune responses in the mucosal compartment is required for protective immunity against viral infection. However, an effective mucosal vaccine against the currently prevalent PEDV strain is not available. In this study, we demonstrated that the N-terminal domain (NTD) of the spike (S) protein of PEDV represents a new vaccine candidate molecule to be applied via the mucosal route. We first established an Escherichia coli expression system producing the partial NTD (NTD(231–501)) of the PEDV S protein. Orally administered NTD(231–501) protein specifically interacted with the apical area of M cells in the follicle-associated epithelium of Peyer's patch. Additionally, the NTD protein induced antigen-specific immune responses in both the systemic and mucosal immune compartments when administered orally. Collectively, we propose the NTD of the PEDV S protein to be a candidate mucosal vaccine molecule. The Korean Association of Immunologists 2018-06-15 /pmc/articles/PMC6026690/ /pubmed/29984039 http://dx.doi.org/10.4110/in.2018.18.e21 Text en Copyright © 2018. The Korean Association of Immunologists https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Sae-Hae Cho, Byeol-Hee Lee, Kyung-Yeol Jang, Yong-Suk N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine |
title | N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine |
title_full | N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine |
title_fullStr | N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine |
title_full_unstemmed | N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine |
title_short | N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine |
title_sort | n-terminal domain of the spike protein of porcine epidemic diarrhea virus as a new candidate molecule for a mucosal vaccine |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026690/ https://www.ncbi.nlm.nih.gov/pubmed/29984039 http://dx.doi.org/10.4110/in.2018.18.e21 |
work_keys_str_mv | AT kimsaehae nterminaldomainofthespikeproteinofporcineepidemicdiarrheavirusasanewcandidatemoleculeforamucosalvaccine AT chobyeolhee nterminaldomainofthespikeproteinofporcineepidemicdiarrheavirusasanewcandidatemoleculeforamucosalvaccine AT leekyungyeol nterminaldomainofthespikeproteinofporcineepidemicdiarrheavirusasanewcandidatemoleculeforamucosalvaccine AT jangyongsuk nterminaldomainofthespikeproteinofporcineepidemicdiarrheavirusasanewcandidatemoleculeforamucosalvaccine |